Arthritis Care & Research is soliciting manuscripts for a themed issue addressing drug safety in the treatment of rheumatic diseases, including but not limited to biologic agents. Manuscripts covering a broad range of topics related to the major theme are invited; for example, update on safety issues related to a specific drug or biologic agent, issues related to classes of treatments (e.g., anti–tumor necrosis factors [anti-TNFs]) and types of events (e.g., opportunistic infections in patients receiving anti-TNF agents), and issues related to different methodologies for assessing safety. Submissions may also describe more general issues related to treatment safety such as new or evolving methods of assessing or discussing safety, or benefit or safety/benefit ratio with patients. Manuscripts from a wide range of disciplines relevant to safety are welcome.
The issues will include regular submissions as well, but a certain number of pages will be reserved for manuscripts accepted in response to this solicitation. Manuscripts will be subject to the usual review process and all types of manuscripts (e.g., original articles, contributions from the field, case studies, trainee rounds, reviews) are included in this solicitation.
The deadline for submission is October 1, 2009. For further information, contact the editors of Arthritis Care & Research, Edward H. Yelin, PhD (Ed.Yelin@ucsf.edu) or Patricia P. Katz, PhD (Patti.Katz@ucsf.edu).